Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene Lab's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.46.
During the past 3 years, the average EBIT per Share Growth Rate was -103.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BioNexus Gene Lab's EBIT per Share or its related term are showing as below:
BGLC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -103.4 Med: 14.4 Max: 119.5
Current: -103.4
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of BioNexus Gene Lab was 119.50% per year. The lowest was -103.40% per year. And the median was 14.40% per year.
BGLC's 3-Year EBIT Growth Rate is ranked worse than 99.25% of 1338
companies
in the Chemicals industry
Industry Median: -1.25
vs BGLC: -103.40
BioNexus Gene Lab (NAS:BGLC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BioNexus Gene Lab EBIT per Share Related Terms
BioNexus Gene Lab EBIT per Share Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a EBIT per Share of $-1.46 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioNexus Gene Lab and its competitors. According to the industry distribution chart, BioNexus Gene Lab ranks #1328 out of 1338 companies in the Chemicals industry, placing it in the top 99.3%.
Is BioNexus Gene Lab's EBIT per Share too high?
BioNexus Gene Lab's current EBIT per Share is $-1.46. Based on the distribution chart, BioNexus Gene Lab ranks #1328 out of 1338 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's EBIT per Share compare to QGAI and VYST?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #1328 out of 1338 companies for EBIT per Share. This places BioNexus Gene Lab in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Chemicals company?
A good EBIT per Share depends on the Chemicals industry context. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioNexus Gene Lab and its competitors. BioNexus Gene Lab's current EBIT per Share is $-1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.68 — trading 22.6% below its estimated fair value. The current EBIT per Share is $-1.46. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current EBIT per Share is $-1.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.68 is trading 22.6% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
EBIT per Share: $-1.46
GF Value™: $2.17 vs. price of $1.68 (22.6% below fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
